Physician profile
Travis Gries
NPI 1891239802
$2,338.91
in general payments reported to CMS, 2019-2025
20 companies · $788 in 2025
The $788 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.40 · 2022: $240 · 2023: $506 · 2024: $791 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,085.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $744.83 | 2022-2025 | Descovy, Epclusa |
| Almatica Pharma LLC | $568.31 | 2023-2025 | Loreev Xr, Teriparatide, Gralise |
| Abbvie INC. | $275.27 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $122.21 | 2022-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Lilly USA, LLC | $107.17 | 2023-2025 | Mounjaro |
| Glaxosmithkline, LLC. | $102.30 | 2023-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Exact Sciences Corporation | $74.20 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Neurocrine Biosciences, INC. | $58.72 | 2022-2025 | Ingrezza |
| Viiv Healthcare Company | $45.01 | 2024 | Apretude |
| Hologic Sales and Service, LLC | $32.29 | 2024 | Aptima, Thinprep 2000 Processor, Affirm Prone Biopsy System |
| Otsuka America Pharmaceutical, INC. | $31.88 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.87 | 2024 | Jardiance |
| Alexion Pharmaceuticals, INC. | $23.12 | 2025 | Koselugo |
| Abbott Laboratories | $23.01 | 2022 | |
| Vanda Pharmaceuticals INC. | $21.58 | 2025 | Fanapt, Hetlioz |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $19.70 | 2025 | |
| Verona Pharma, INC. | $18.18 | 2025 | Ohtuvayre |
| Sanofi Pasteur INC. | $16.95 | 2024 | |
| Idorsia Pharmaceuticals US INC | $14.91 | 2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $13.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Gries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.